Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.
Million A TegengeH YangR A ForsheePublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2017)
The results of the study demonstrate the feasibility of individualizing infusion interval, restricting FVIII dose, trough and peak concentration within an acceptable range.
Keyphrases